---
title: "CTSO.US (CTSO.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CTSO.US/news.md"
symbol: "CTSO.US"
name: "CTSO.US"
parent: "https://longbridge.com/en/quote/CTSO.US.md"
datetime: "2026-05-20T07:17:32.209Z"
locales:
  - [en](https://longbridge.com/en/quote/CTSO.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CTSO.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CTSO.US/news.md)
---

# CTSO.US (CTSO.US) — Related News

### [Transcript: CytoSorbents Q1 2026 Earnings Conference Call](https://longbridge.com/en/news/286321631.md)
*2026-05-13T21:36:10.000Z*
> CytoSorbents (NASDAQ:CTSO) reported a 2% year-over-year revenue growth to $8.9 million for Q1 2026, despite geopolitical

### [CytoSorbents | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 8.864 M](https://longbridge.com/en/news/286313018.md)
*2026-05-13T20:29:34.000Z*
### [CytoSorbents | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 8.864 M](https://longbridge.com/en/news/286310038.md)
*2026-05-13T20:11:14.000Z*
### [CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | CTSO Stock News](https://longbridge.com/en/news/286308377.md)
*2026-05-13T12:00:48.000Z*
> CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | CTSO Stoc

### [CTSO Q1'26 Earnings: EPS estimate is (0.05) USD](https://longbridge.com/en/news/285061049.md)
*2026-05-04T11:01:16.000Z*
> CTSO (Cytosorbents Corporation) is set to announce its Q1'26 results on May 05, time not specified. The earnings are exp

### [CytoSorbents Receives Nasdaq Extension to Regain Compliance](https://longbridge.com/en/news/281517355.md)
*2026-04-02T11:42:48.000Z*
> CytoSorbents Corporation has received a 180-day extension from Nasdaq until September 28, 2026, to regain compliance wit

### [Cytosorbents 10-K: Revenue $37.1M, EPS not disclosed](https://longbridge.com/en/news/281008093.md)
*2026-03-30T11:15:01.000Z*
> Cytosorbents reported fiscal 2025 revenue of $37.1 million, a 4.1% increase from 2024, with a narrowed net loss of $8.2 

### [CytoSorbents | 10-K: FY2025 Revenue Misses Estimate at USD 37.06 M](https://longbridge.com/en/news/281006388.md)
*2026-03-30T11:08:30.000Z*